

Supplemental Information

Targeting trimeric transmembrane domain 5 of oncogenic latent membrane protein 1 using a computationally designed peptide

Yibo Wang ‡, Yinghua Peng ‡, Bo Zhang, Xiaozheng Zhang, Hongyuan Li, Andrew J. Wilson, Konstantin S. Mineev and Xiaohui Wang*

Materials and Methods

Rosetta design

The homotrimer of TMD5 was homology modeled according to a reasonable NMR coiled-coil structure (PDB ID 1AQ5) and validated via experiments previously^{1, 2}. The anti-TMD5 peptide was designed using the Rosetta molecular modelling package³. The previously built model of TMD5 trimeric complex was used as the template and chain A was defined as the origin for the design of anti-TMD5². The hydrogen-bonding network between the aspartic acid residues at position 150 was determined to be a driving force for the trimerization of the TMD5 peptides, thus the aspartic acid was retained in the anti-TMD5 peptide design. The identities for all remaining anti-TMD5 sequence positions located at the trimeric interface were allowed to vary, while alternate side-chain conformations were sampled for the wild-type TMD5 peptides in order to search for a lower energy structure. A version of the Rosetta energy function with a dampened Lennard-Jones repulsion potential was used⁴. 50 designs were generated, and an anti-TMD5 sequence with the lowest score was selected for characterization based on the RosettaDesign energy function⁵⁻⁸.

Molecular dynamics simulations

The homotrimeric TMD5 and the heterotrimer (one anti-TMD5 helix with lowest score in Rosetta and two wild type TMD5 helices) were embedded in a 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) bilayer and solvated in a 62×62×78 Å³ box filled with TIP3P water molecules via the CHARMM-GUI membrane builder protocol⁹. 150 mM KCl was added to neutralize the system and mimic the physiological concentration. The protein, lipids, and ions were described by the CHARMM36 force field^{10, 11} and all MD simulations were performed by the NAMD2.12 program package¹².

The models with ~30,000 atoms were simulated under the NPT ensemble with a pressure of 1 atm at 310.15 K. The Nosé-Hoover Langevin piston method^{13, 14} was applied for the pressure control and the Langevin thermostat for the temperature coupling. Long-range electrostatic interactions were treated by the particle mesh Ewald (PME) algorithm¹⁵. Non-bonded interactions were switched off at 10 ~ 12 Å. Periodic boundary conditions were applied in all directions and the time step was set as 2 fs. After a staged equilibration with a gradual decrease in harmonic constraints that act on heavy lipid and protein atoms only, further non-constrained relaxations were run for 100 ns for analysis.

Peptide synthesis

TMD5, Coumarin-tagged TMD5, anti-TMD5, FITC-tagged anti-TMD5, anti-TMD5 scramble, and FITC-tagged anti-TMD5 scramble were prepared by standard microwave-assisted solid-phase synthesis. The purity and identity of these peptide were confirmed by HPLC (>95%) and mass spectrometry (see Appendix Data). The concentrations of anti-TMD5/anti-TMD5 scramble and TMD5 were determined by absorbance at 280 nm using the extinction coefficient of 34490 M⁻¹cm⁻¹ and 6990 M⁻¹cm⁻¹, respectively. The concentration of coumarin labeled TMD5 peptide was determined by absorbance at 400 nm using an extinction coefficient of 39300 M⁻¹cm⁻¹. The concentration of FITC-tagged anti-TMD5/FITC-tagged anti-TMD5 scramble was determined by absorbance at 495 nm using an extinction coefficient of 84000 M⁻¹cm⁻¹.

Peptide Sequence:

TMD5	KKKK-WQLLAFFLAFFLDLILLI IALYL-KKKK
Coumarin-tagged TMD5	coumarin-GKKKK-WQLLAFFLAFFLDLILLI IALYL-KKKK
anti-TMD5	KKKK-WWKLWYFLVWFDLI I I I I L L W W-KKKK
FITC-tagged anti-TMD5	FITC-GKKKK-WWKLWYFLVWFDLI I I I I L L W W-KKKK
anti-TMD5 scramble	KKKK-VFLWLWLIWIFIDWKLWLLYWLL-KKKK
FITC-tagged anti-TMD5 scramble	FITC-GKKKK-VFLWLWLIWIFIDWKLWLLYWLL-KKKK

Fluorescence dequenching assay

100 µL of coumarin-tagged TMD5 peptide (50 nM) solution (50 mM HEPES, 150 µM C14 betaine, pH = 7.4) with the indicated concentration of unmodified anti-TMD5/anti-TMD5 scramble or NSC 259242 was pipetted into black 96-well plates in triplicate. Samples were mixed and allowed to sit at room temperature in the dark overnight to reach equilibrium and then excited at 360 nm and emission was read at 430 nm using a SYNERGY H1 Micro-plate Reader (BioTek Instruments, Carlsbad, CA, USA). The relative fluorescence intensity was normalized by TMD-5 fluorescence in the absence of TMD-5 inhibitor.

FRET assay

Fluorescence resonance energy transfer (FRET) experiments were conducted under room temperature in a 2×10 mm quartz cell (Starna Cells, Atascadero, CA, USA) on a Cary Eclipse spectrofluorimeter (Agilent Technologies, Santa Clara, CA, USA). 50 nM (7-hydroxy-3-carboxamide coumarin)-labeled TMD5 peptide in 20 mM HEPES, pH = 7.4 and 1.0 mM C14 betaine micelles (or 1.0 mM bicelles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and dihexanoylphosphatidylcholine (DHPC), q = 0.3) buffer was titrated with increasing concentrations of FITC-tagged anti-

TMD5 or FITC-tagged anti-TMD5 scramble. 415 nm was chosen as the excitation. Emission at 400-600 nm was recorded. Samples containing the same amount of fluorescence acceptor (FITC-tagged anti-TMD5/ FITC-tagged anti-TMD5 scramble) served as a reference. The net FRET signals (total signal - reference signal) were used. The quenching of fluorescence signal of coumarin-labeled TMD5 peptide was analyzed by the equation, $\log (F_0/F-1) = -\log K_d + n \times \log ([\text{FITC-tagged anti-TMD5}])$.

Dominant-negative ToxR assay

Plasmids for this assay, pTox7 and pTox6, and the competent *E. coli* strain, FHK12, were kindly provided by Dr. Langosh, Technische Universität München, Germany. The pTox7 plasmid was modified by insertion of a single base (T) after the BamHI site to keep the proper reading frame for the designed transmembrane sequences^{16,17}. TMD5-ToxR (pTox7-TMD5), anti-TMD5-ToxR* (pTox6-TMD5), anti-TMD5 scramble-ToxR* (pTox6-TMD5 scramble) and poly Leu-ToxR* (pTox6-poly Leu) constructs were made as described previously^{16,17}.

ToxR construct (200 ng) and ToxR* construct (200 ng) were transformed into *E. coli* strain FHK12 by heat shock method. 50 μL of each transformation was used to inoculate, in triplicate, 5 mL of Luria-Bertani broth containing chloramphenicol (35 $\mu\text{g}/\text{mL}$), kanamycin (33 $\mu\text{g}/\text{mL}$) and 0.0025% arabinose. Cultures were incubated with shaking at 37 °C for 20 h and β -galactosidase activity was measured using a Beckman Coulter DTX 880 plate reader (Beckman Coulter, CA, USA). Briefly, 5 μL of culture was transferred to the wells of a Costar 3596 polystyrene 96-well plate (Corning, NY, USA) containing 100 μL Z buffer/chloroform (1% β -mercaptoethanol, 10% chloroform, 89% A buffer: 1 M sodium phosphate, 10 mM KCl, 1 mM MgSO_4 and pH 7.0). Cells were lysed by addition of 50 μL Z buffer/ SDS (1.6% w/v sodium dodecyl sulfate in Z buffer) and shaking at 28 °C for 10 min. 50 μL Z buffer/ *o*-nitro phenyl galactoside (ONPG, 0.4% w/v in Z buffer) was added and β -galactosidase activity was measured by monitoring the reaction at 405 nm for a period of 20 min at 28°C. Miller units were calculated using the following equation: Miller units = $(\text{OD}_{405 \text{ nm}}/\text{min})/\text{OD}_{600 \text{ nm}} \times 1000$.

NF- κ B assay

B lymphoblastoid 721 cell line NF- κ B reporter cell was constructed previously¹⁸, where the firefly luciferase gene was placed under the control of the NF- κ B transcriptional response element. B721 NF- κ B reporter cells were cultured in RPMI medium supplemented with 10% fetal bovine serum (FBS), penicillin (50 unit/mL) and streptomycin (50 $\mu\text{g}/\text{mL}$). Cells were seeded at a density of 1×10^4 cells/well in 96-well plates (100 $\mu\text{L}/\text{well}$). After overnight incubation, different concentrations of peptide were added to the cells. Following 24 h of treatment, the NF- κ B activity was detected by Steady-Glo Luciferase Assay System (Promega, Madison, MI, USA) according to manufacturer's instructions. Briefly, 75 μL Steady-Glo Luciferase Assay reagent was added to each well and incubated at room temperature for 15 min. The luminescence was subsequently measured.




Fig. S1. Computational models for homotrimer and heterotrimer: (a) Sequences of the TMD5 and anti-TMD5 in a trimeric conformation. The variant residues in anti-TMD5 were labelled in red. (b) Backbone RMSD of homotrimer (black) and heterotrimer_1:2 (one anti-TMD5 and two TMD5s) (red) in 100 ns equilibrium molecular dynamics simulations. Both systems reached a stable state within 10 ns.




Fig. S2. Key residues stabilizing the oligomerization in the trimer.




Fig. S3. Circular dichroism spectrum of anti-TMD5 in C14 betaine micelles showing an α -helical secondary structure. CD measurements were performed on a Jasco J-1500 CD spectrophotometer at room temperature. Anti-TMD5 peptides were co-dissolved in 2,2,2-trifluoroethanol (Sigma-Aldrich, St. Louis, MO, USA) and C14 betaine (3-(*N,N*-dimethylmyristylammonio)propanesulfonate; Sigma-Aldrich, St. Louis, MO, USA). The organic solvent was removed under reduced pressure to generate a thin film of peptide/detergent mixture, which was then dissolved in 100 mM HEPES buffer (pH = 7.4). The final concentration of C14 betaine was 1 mM in the samples. Far UV CD spectra (200 – 260 nm) were acquired using a cell path length of 0.1 cm and the results were expressed as mean residue ellipticity $[\theta]_{\lambda}$ in $\text{deg}\cdot\text{cm}^2\cdot\text{dmol}^{-1}$ at a given wavelength λ (nm) using the relation: $[\theta]_{\lambda} = \theta_{\lambda} \times M_0 / (10 \times c \times l)$, where θ_{λ} is the observed ellipticity in millidegrees at wavelength λ , M_0 is the mean residue weight of the protein, c is the protein concentration (mg/cm^3), and l is the path length (cm). It should be noted that each observed θ_{λ} of the protein was corrected for the contribution of the buffer. Data were not collected below 200 nm due to the high voltage and background noise from the C14 Betaine buffer. The α -helical content of peptide was calculated according to equation¹⁹: $\alpha\text{-Helix (\%)} = -([\theta]_{222\text{ nm}} + 2340) / 30300 \times 100$.




Fig. S4. FRET assay: (a) Fluorescence emission scans of coumarin-tagged TMD5 (50 nM) in the presence of different concentrations of FITC-tagged anti-TMD5 scramble in 20 mM HEPES, pH = 7.4, containing 1.0 mM C14 betaine at room temperature. λ_{ex} was set at 415 nm to selectively excite the coumarin. λ_{ex} , excitation wavelength; (b) Stern-Volmer quenching plots of coumarin labelled TMD5 fluorescence by anti-TMD5 scramble or anti-TMD5 binding. The Stern-Volmer constant of anti-TMD5 scramble ($0.14 \pm 0.02 \mu\text{M}^{-1}$) is much weaker than that of anti-TMD5 ($0.58 \pm 0.04 \mu\text{M}^{-1}$).




Fig. S5. The quenching of fluorescence signal from coumarin-labeled TMD5 peptide by FITC-tagged anti-TMD5 in 20 mM HEPES, pH = 7.4, containing 1.0 mM bicelles composed of POPC and DHPC ($q = 0.3$). The data analyzed by the equation, $\log(F_0/F-1) = -\log K_d + n \times \log([\text{anti-TMD5}])$. A stoichiometry $n = 0.44 \pm 0.03$ and an apparent K_d of 40.0 ± 6.7 nM were obtained.




Fig. S6. Locations of four water molecules in heterotrimer_2:1 (two anti-TMD5s and one TMD5). The distance between the oxygen of each water molecule and the center of mass of the $C\alpha$ of heterotrimer_2:1 were calculated and represented by black, red, blue, and magenta lines, respectively. The location of four water molecules in heterotrimer_2:1 was displayed and numbered with 1, 2, 3, and 4. W139 and D150 were represented in cyan sticks.




Fig. S7. Cell viability assay. B721 cells were stimulated for indicated concentrations of anti-TMD5 and anti-TMD5 scramble. Higher concentrations ($> 4 \mu\text{M}$) were not tested because of their poor solubility. TMD5/anti-TMD5 stock solutions were prepared as following: They were dissolved in 2,2,2-trifluoroethanol. The organic solvent was removed under reduced pressure to generate a thin film of peptide, which was then dissolved in 20 mM HEPES buffer (pH=7.4) containing micelle (C14 betaine) or bicelles (POPC/DHPC or DMPC/DHPC). Following 24 h treatment, 20 μL of Cell Proliferation Reagent WST-1 (Roche Diagnostics GmbH, Mannheim, Germany) was added. After further incubation at 37 $^{\circ}\text{C}$ for 1–2 h, the absorbance at 450 nm was measured on a SYNERGY HI Micro-plate Reader (BioTek Instruments, Carlsbad, CA, USA) and 620 nm was chosen as the reference wavelength. The $A_{450 \text{ nm}}/A_{620 \text{ nm}}$ for the control group was set as 100%.

References

1. S. A. Dames, R. A. Kammerer, R. Wiltschek, J. Engel and A. T. Alexandrescu, *Nat. Struct. Biol.*, 1998, **5**, 687-691.
2. D. W. Sammond, C. Joce, R. Takeshita, S. E. McQuate, N. Ghosh, J. M. Martin and H. Yin, *Biopolymers*, 2011, **95**, 772-784.
3. C. A. Rohl, C. E. Strauss, K. M. Misura and D. Baker, *Methods Enzymol.*, 2004, **383**, 66-93.
4. G. Dantas, C. Corrent, S. L. Reichow, J. J. Havranek, Z. M. Eletr, N. G. Isern, B. Kuhlman, G. Varani, E. A. Merritt and D. Baker, *J. Mol. Biol.*, 2007, **366**, 1209-1221.
5. V. D. Sood and D. Baker, *J. Mol. Biol.*, 2006, **357**, 917-927.
6. R. Jacak, A. Leaver-Fay and B. Kuhlman, *Proteins*, 2012, **80**, 825-838.
7. B. Kuhlman and D. Baker, *P. Natl. Acad. Sci. USA*, 2000, **97**, 10383-10388.
8. C. A. Rohl, C. E. M. Strauss, K. M. S. Misura and D. Baker, *Methods Enzymol.*, 2004, **383**, 66-93.
9. S. Jo, T. Kim, V. G. Iyer and W. Im, *J. Comput. Chem.*, 2008, **29**, 1859-1865.
10. R. B. Best, X. Zhu, J. Shim, P. E. Lopes, J. Mittal, M. Feig and A. D. Mackerell, Jr., *J. Chem. Theory. Comput.*, 2012, **8**, 3257-3273.
11. J. B. Klauda, R. M. Venable, J. A. Freites, J. W. O'Connor, D. J. Tobias, C. Mondragon-Ramirez, I. Vorobyov, A. D. MacKerell, Jr. and R. W. Pastor, *J. Phys. Chem. B*, 2010, **114**, 7830-7843.
12. J. C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R. D. Skeel, L. Kale and K. Schulten, *J. Comput. Chem.*, 2005, **26**, 1781-1802.
13. G. J. Martyna, D. J. Tobias and M. L. Klein, *J. Chem. Phys.*, 1994, **101**, 4177-4189.
14. S. E. Feller, Y. H. Zhang, R. W. Pastor and B. R. Brooks, *J. Chem. Phys.*, 1995, **103**, 4613-4621.
15. U. Essmann, L. Perera, M. L. Berkowitz, T. Darden, H. Lee and L. G. Pedersen, *J. Chem. Phys.*, 1995, **103**, 8577-8593.
16. C. Joce, A. Wiener and H. Yin, *J. Vis. Exp.*, 2011, **51**, e2721.
17. J. I. Godfroy, 3rd, M. Roostan, Y. S. Moroz, I. V. Korendovych and H. Yin, *PLoS One*, 2012, **7**, e48875.
18. X. H. Wang, Z. Fiorini, C. Smith, Y. N. Zhang, J. Li, L. R. Watkins and H. Yin, *PLOS One*, 2012, **7**, e47703.
19. Q. Shi, X. Wang and J. Ren, *Biophys. Chem.*, 2008, **138**, 138-143.

Appendix data:
HPLC and mass spectrometry characterizations of the synthesized peptides

- a. TMD5
- b. Coumarin labeled TMD5
- c. Anti-TMD5
- d. FITC-labeled anti-TMD5
- e. Anti-TMD5 scramble
- f. FITC-labeled anti-TMD5 scramble

HPLC Report of TMD5

Structure : TMD5

Column : 4.6×250mm,Venusil MP C18-5

Solvent A : 0.1% trifluoroacetic in 100% acetonitrile


Solvent B : 0.1% trifluoroacetic in 100% water

Gradient : A B
0.01min 55% 45%
25min 100% 0%
25.1min 100% 0%
30min STOP

Flow rate : 1.0 mL/min


Wavelength : 220nm

Volume : 5ul



Peak No.	Ret Time	Height	Area	Conc..
1	8.553	335.982	2560.503	0.0601
2	8.920	1142.773	8896.888	0.2089
3	10.797	7004.221	75740.398	1.7785
4	11.185	490966.563	4109966.750	96.5070
5	11.185	5274.425	61557.281	1.4454
Total			100.0000	

Mass Spectrometry Report of TMD5



Sample Description

Analyzed date: 2016-11-15
 Analyst: YU
 Sample: TMD5
 M.W.: 3795.91
 Lot No.: P161111-SY545400

Instrument

Probe:
 Nebulizer Gas Flow:
 CDL:
 CDL Temp.:
 Block Temp.:

Waters ZQ2000

ESI
 1.5L/min
 -20.0v
 250 °C
 200 °C

Probe Bias:
 Detector:
 T.Flow:
 B. Conc.:

+4.5kv
 1.5kv
 0.2ml/min
 50%H2O/50%ACN

HPLC Report of Coumarin-tagged TMD5

Structure : coumarin-labeled TMD5

Column : 4.6×250mm,Venusil MP C18-5

Solvent A : 0.1% trifluoroacetic in 100% acetonitrile


Solvent B : 0.1% trifluoroacetic in 100% water

Gradient : A B
0.01min 50% 50%
25min 100% 0%
25.1min 100% 0%
30min STOP

Flow rate : 1.0 mL/min


Wavelength : 220nm

Volume : 5ul



Peak No.	Ret Time	Height	Area	Conc..
1	11.410	1141.444	17451.203	0.2892
2	12.193	21842.223	179035.031	2.9671
3	12.520	279863.688	5757074.500	95.4093
4	13.180	1310.283	17379.811	0.2880
5	20.142	2148.968	63140.801	1.0464
Total			100.0000	

Mass Spectrometry Report of Coumarin-tagged TMD5



Sample Description		Instrument	Waters ZQ2000	
Analyzed date:	2016-12-01	Probe:	ESI	Probe Bias: +4.5kv
Analyst:	YU	Nebulizer Gas Flow:	1.5L/min	Detector: 1.5kv
Sample:	coumarin-labeled TMD5	CDL:	-20.0v	T.Flow: 0.2ml/min
M.W.:	4068.96	CDL Temp.:	250 °C	B. Conc.: 50%H2O/50%ACN
Lot. No.:	P161124-SY545401	Block Temp.:	200 °C	

HPLC Report of anti-TMD5

Product Name: anti-TMD5

Column : 4.6*250mm, 4.6*250mm, SP-300-10-UniPS

Solvent A : 0.1% Trifluoroacetic in 100% Acetonitrile


Solvent B : 0.1% Trifluoroacetic in 100% Water

Gradient : A B
 0.00min 50% 50%
 25min 100% 0%
 25.1min 100% 0%
 30min Stop

Flow rate : 1.0ml/min


Wavelength : 220nm

Volume : 10ul



Rank	Time	Conc.	Area	Height
1	12.453	1.4999	78597	9370
2	12.800	95.4406	5001272	247340
3	13.540	3.0595	160326	7179
Total		100	5240195	263889

Mass Spectrometry Report of anti-TMD5



Sample Description	Instrument	Agilent-6125B		
Analyzed date: 2017-03-07	Probe:	ESI	Probe Bias:	+4.5kv
Analyst: YU	Nebulizer Gas Flow:	1.5L/min	Detector:	1.5kv
Sample: anti-TMD5	CDL:	-20.0v	T.Flow:	0.2ml/min
M.W.: 4205.41	CDL Temp.:	250 °C	B. Conc.:	50%H2O/50%ACN
Lot. No.: P190220-SL709219	Block Temp.:	200 °C		

HPLC Report of FITC-tagged anti-TMD5

Product Name: FITC-labeled anti TMD5

Column : 4.6*250mm, 4.6*250mm, SP-300-10-UniPS

Solvent A : 0.1% Trifluoroacetic in 100% Acetonitrile


Solvent B : 0.1% Trifluoroacetic in 100% Water

Gradient : A B
 0.00min 50% 50%
 25min 100% 0%
 25.1min 100% 0%
 30min Stop

Flow rate : 1.0ml/min


Wavelength : 220nm

Volume : 10ul



Rank	Time	Conc.	Area	Height
1	13.830	1.4234	55629	2349
2	14.136	96.8997	3787026	271602
3	15.093	1.2812	50071	2288
4	15.740	0.3957	15464	1542
Total		100	3908190	277781

Mass Spectrometry Report of FITC-tagged anti-TMD5



Sample Description

Analyzed date: 2017-03-07
 Analyst: YU
 Sample: FITC-labeled anti TMD5
 M.W.: 4765.01
 Lot. No.: P190220-SL709220

Instrument

Probe:
 Nebulizer Gas Flow:
 CDL:
 CDL Temp.:
 Block Temp.:

Agilent-6125B

ESI
 1.5L/min
 -20.0v
 250 °C
 200 °C
 Probe Bias: +4.5kv
 Detector: 1.5kv
 T.Flow: 0.2ml/min
 B. Conc.: 50%H2O/50%ACN

HPLC Report of Anti-TMD5 Scramble

Product Name: anti-TMD5 scramble

Column : 4.6*250mm, GS-120-5-C18-BIO

Solvent A : 0.1% Trifluoroacetic in 100% Acetonitrile


Solvent B : 0.1% Trifluoroacetic in 100% Water

Gradient : A B
 0.00min 40% 60%
 25min 65% 35%
 25.1min 100% 0%
 30min Stop

Flow rate : 1.0ml/min

Wavelength : 220nm

Volume : 10ul




Rank	Time	Conc.	Area	Height
------	------	-------	------	--------

1	12.000	1.5470	65093	0
2	13.313	97.0118	4081893	84156
3	14.450	1.4412	60642	4277

Total	100	4207628	88433	
-------	-----	---------	-------	--

Mass Spectrometry Report of Anti-TMD5 Scramble



Sample Description		Instrument	Agilent-6125B		
Analyzed date:	2017-03-22	Probe:	ESI	Probe Bias:	+4.5kv
Analyst:	YU	Nebulizer Gas Flow:	1.5L/min	Detector:	1.5kv
Sample:	anti-TMD5 scramble	CDL:	-20.0v	T.Flow:	0.2ml/min
M.W.:	4205.41	CDL Temp.:	250 °C	B. Conc.:	50%H2O/50%ACN
Lot. No.:	P190313-SL714398	Block Temp.:	200 °C		

HPLC Report of FITC-tagged anti-TMD5 scramble

Product Name:FITC-anti-TMD5 scramble

Column :4.6*250mm, GS-120-5-C18-BIO

Solvent A :0.1%Trifluoroacetic in 100% Acetonitrile


Solvent B :0.1%Trifluoroacetic in 100% Water

Gradient : A B
 0.00min 40% 60%
 25min 65% 35%
 25.1min 100% 0%
 30min Stop

Flow rate :1.0ml/min

Wavelength :220nm


Volume :10ul



Rank	Time	Conc.	Area	Height
1	9.223	0.1294	9381	1016
2	10.173	0.4198	30441	3126
3	12.502	1.0548	76492	5018
4	13.208	96.9865	7033302	162959
5	14.303	1.4095	102217	4763

Total 100 7251833 176882

Mass Spectrometry Report of FITC-tagged anti-TMD5 scramble



Sample Description	Instrument	Agilent-6125B	
Analyzed date: 2017-03-25	Probe:	ESI	Probe Bias: +4.5kv
Analyst: YU	Nebulizer Gas Flow:	1.5L/min	Detector: 1.5kv
Sample: FITC-anti-TMD5 scramble	CDL:	-20.0v	T.Flow: 0.2ml/min
M.W.: 4765.01	CDL Temp.:	250 °C	B. Conc.: 50%H2O/50%ACN
Lot. No.: P190313-SL714400	Block Temp.:	200 °C	